MARKET

CATX

CATX

Perspective Therapeutics Inc
AMEX
1.590
-0.040
-2.45%
Closed 19:11 05/21 EDT
OPEN
1.630
PREV CLOSE
1.630
HIGH
1.650
LOW
1.495
VOLUME
4.06M
TURNOVER
0
52 WEEK HIGH
1.905
52 WEEK LOW
0.2050
MARKET CAP
989.98M
P/E (TTM)
-15.6805
1D
5D
1M
3M
1Y
5Y
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Healthcare Eli Lilly inks radiopharma deal worth up to $ with Aktis Oncology. Aktis will receive a $60M upfront payment. Eli Lilly will leverage Aktis’ radiopharmaceutical platform to develop cancer-targeting drugs.
Seeking Alpha · 1d ago
Weekly Report: what happened at CATX last week (0513-0517)?
Weekly Report · 2d ago
Perspective Therapeutics to Present at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024
Perspective Therapeutics, Inc. Will present information at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting 2024. The company is pioneering advanced treatment applications for cancers throughout the body. The Company will present results from sponsored studies of its assets in Toronto, Canada.
Barchart · 2d ago
Perspective Therapeutics Is Maintained at Buy by Jones Trading
Dow Jones · 6d ago
Perspective Therapeutics Price Target Raised to $2.20/Share From $1.50 by Jones Trading
Dow Jones · 6d ago
Jones Trading Maintains Buy on Perspective Therapeutics, Raises Price Target to $2.2
Benzinga · 6d ago
Perspective Therapeutics, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/15 20:41
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and Unicycive Therapeutics (UNCY)
TipRanks · 05/15 17:30
More
About CATX
Perspective Therapeutics, Inc. is a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents. The Company is focused on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies, so its targeted medical doses are delivered directly to the tumor site. The Company’s core product is its Cesium-131 sealed source brachytherapy seed. These seeds can be inserted individually or in combination into various locations in the body. The Company also sells seeds in strands to keep them from individually moving. The Company’s segments are Brachytherapy and Drug Operations. Brachytherapy includes sales and manufacturing of Cesium-131 brachytherapy seeds, including research and development of new applications for the seeds. Drug Operations includes research and development and clinical operations related to the use of Lead-203 and Lead-212 as a diagnostic and a therapeutic drug.

Webull offers Perspective Therapeutics Inc stock information, including AMEX: CATX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CATX stock methods without spending real money on the virtual paper trading platform.